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Background: Metformin, a widely used hypoglycemic drug, reduces stroke incidence and alleviates chronic
inflammation in clinical trials. However, the effect of metformin in ischemic stroke is unclear. Here, we investigated
the effect of metformin on ischemic stroke in mice and further explored the possible underlying mechanisms.
Methods: Ninety-eight adult male CD-1 mice underwent 90-minute transient middle cerebral artery occlusion
(tMCAO). Metformin (200 mg/kg) was administrated for up to 14 days. Neurobehavioral outcomes, brain infarct
volume, inflammatory factors, blood-brain barrier (BBB) permeability and AMPK signaling pathways were evaluated
following tMCAO. Oxygen glucose deprivation was performed on bEND.3 cells to explore the mechanisms of
metformin in inhibiting inflammatory signaling pathways.
Results: Infarct volume was reduced in metformin-treated mice compared to the control group following tMCAO
(P < 0.05). Neurobehavioral outcomes were greatly improved in metformin-treated mice (P < 0.05). MPO+ cells, Gr1+
cells, MPO activity and BBB permeability were decreased after metformin administration (P < 0.05). In addition,
metformin activated AMPK phosphorylation, inhibited NF-κB activation, down-regulated cytokine (IL-1β, IL-6, TNF-α)
and ICAM-1 expression following tMCAO (P < 0.05). Furthermore, metformin activated AMPK signaling pathway and
alleviated oxygen-glucose deprivation-induced ICAM-1 expression in bEND.3 cells (P < 0.05). Compound C, a selective
AMPK inhibitor, eliminated this promotional effect.
Conclusions: Metformin down-regulated ICAM-1 in an AMPK-dependent manner, which could effectively prevent
ischemia-induced brain injury by alleviating neutrophil infiltration, suggesting that metformin is a promising therapeutic
agent in stroke therapy.
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Ischemic stroke is the second leading cause of death
worldwide [1]. Due to its high disability, it is also a big
burden on our society. So far, the only Food and Drugs
Administration (FDA) approved drug for the treatment
of ischemic stroke is rtPA, which improves clinical out-
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unless otherwise stated.onset. However, due to its narrow therapeutic window,
less than 5% of patients benefit from it [2]. Therefore,
developing effective drugs to treat ischemic stroke is an
important task.
Metformin is a drug widely prescribed for the treat-
ment of type 2 diabetes and other metabolic syndromes
since 1960s [3]. Through activating AMP-activated kin-
ase (AMPK), metformin inhibits hepatic glucose produc-
tion and increases peripheral glucose utilization, which
effectively controls blood glucose level [4]. However, its
ability is not limited to lowering glucose. The benefits of
metformin have been demonstrated in clinical trials.
Metformin reduces stroke incidence and diabetes relatedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Experimental design. Graph illustrating the experimental
design including transient middle cerebral artery occlusion (tMCAO),
metformin administration, infarct volume, protein expression and
neurobehavioral assessments.
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molecule-1 (ICAM-1) and vascular cell adhesion molecule-
1 (VCAM-1) levels in plasma and alleviates chronic in-
flammation in patients [6]. Nevertheless, these effects were
independent of its glycemic management properties, sug-
gesting that metformin may have other functions through
mechanisms other than glucose reduction. AMPK is a tri-
metric enzyme comprising a catalytic α-subunit and regu-
latory β- and γ-subunits [7]. An alteration in AMP/ATP
ratio activates AMPK and promotes AMPK phosphoryl-
ation at a threonine residue (Thr-172) [3]. A series of
pathological conditions such as glucose deprivation, ische-
mia, starvation and oxidative stress increase AMPK activ-
ity [8]. Agents such as resveratrol and adiponectin can
also activate AMPK. AMPK activation is a protective reac-
tion that occurs after injury. AMPK activated by metfor-
min showed to reduce endothelial cell apoptosis and
diminish cardiomyocyte death [9,10]. It has been demon-
strated that increasing AMPK activity in neurons protects
neurons from various injuries [11]. In addition, metformin
reduced TNF-α-induced inflammation via activation of
AMPK in vascular endothelial cells (ECs) [12]. It has been
indicated that AMPK activation in cells in the immune
system promotes the switch from a pro-inflammatory to
an anti-inflammatory phenotype [13]. Thus, metformin
could be a promising anti-inflammatory agent.
ICAM-1 is expressed on many cell types including ECs
and lymphocytes [14]. ICAM-1 is expressed constitutively
on ECs at low level and its expression is significantly in-
creased in hypoxic condition [15]. ICAM-1 expressed on
ECs facilitates neutrophil adhesion and tissue infiltration,
which play critical roles in the progress of ischemic stroke
[16,17]. Infiltrated leukocytes induce a secondary injury
after reperfusion by producing detrimental substances that
damage brain cells and disrupt the blood-brain barrier
(BBB) [18,19]. BBB disruption after ischemia increases
brain edema and exacerbates ischemic injury [14]. Since
ICAM-1 plays a vital role in neutrophil infiltration and
cerebral injury after reperfusion, it is a promising target in
the treatment of ischemic stroke.
Studies have illustrated that metformin provides cardi-
oprotection against myocardial infarction [4]. However,
the function of metformin in inflammation after ische-
mic stroke is unknown. In our research, we explored
whether metformin could reduce ischemic brain injury
using a mouse transient middle cerebral artery occlusion




Animal protocol was approved by the Institutional Animal
Care and Use Committee of Shanghai Jiao Tong University,
Shanghai, China. Ninety-eight adult male CD1 mice weredivided into two groups that either underwent metformin
or saline treatment. At 1 and 3 days after tMCAO, mice
were sacrificed and samples were collected for further
study. Metformin (Sigma, St. Louis, MO, USA) was dis-
solved in sterile saline at a concentration of 30 mg/ml and
200 mg/kg was administered intra-peritoneally immediately
after reperfusion and then administered daily until the ani-
mals were sacrificed. An equal volume of saline was used
for the control group. The dose was chosen according to a
previous study [20]. The whole experimental design and
the number of animal used are displayed in Figure 1.
Transient middle cerebral artery occlusion (tMCAO)
in mice
tMCAO was carried out as previously described [21].
Adult CD1 mice weighing 30 ± 5 grams were anesthetized
with ketamine/xylazine (100 mg/10 mg/kg; Sigma, St.
Louis, MO, USA) through intra-peritoneal injection. After
isolation of the left common carotid artery, the external
carotid artery (ECA) and the internal carotid artery (ICA),
a silicone-coated 6-0 suture (Covidien, Mansfield, MA,
USA) was gently inserted into the ICA and stopped at the
opening of the middle cerebral artery (MCA). Successful
occlusion was ascertained by a decrease of surface cerebral
blood flow to 10% of baseline using a laser Doppler flow-
metry (Moor Instruments, Devon, UK). Reperfusion was
performed 90 minutes after tMCAO with suture with-
drawal. Sham-operated mice underwent the same proced-
ure except for the insertion of the suture into the ICA.
The mortality in our study was less than 5%.
Infarct volume measurement
Infarct volume was measured using cresyl violet (Sigma,
St. Louis, MO, USA) staining as previously described [22].
The ischemic area of each section was depicted by image
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volume was calculated as described in our previous
study [23].
Neurobehavioral assessments
Neurobehavioral assessments were conducted by an ex-
perimenter who was blind to the treatment conditions.
The rotarod test was used to evaluate the motor and bal-
ance functions of the mice. The mice were trained to
stay on an accelerating rotating cylinder for 3 days be-
fore tMCAO, and time remained on the rotating rod
was recorded before surgery and at 1, 3, 7 and 14 days
after surgery. The velocity was increased slowly from 4 to
40 rpm within 2 minutes. For each test, every animal was
tested three times, and the average time maintained on
the rod was recorded. For neurological function assess-
ment, a modified Neurological Severity Scores (mNSS)
ranging from 0 to 14 score was adopted, which included
raising the mouse by the tail (0 to 3), walking on the floor
(0 to 3), beam balance tests (0 to 6), and the relaxes ab-
sence (0 to 2) [22].
Immunostaining
Double staining: ZO-1/CD31, occludin/CD31 or claudin-
5/CD31 double staining was conducted as previously de-
scribed [23]. Briefly, brain sections were blocked with 10%
FBS for 1 hour and then incubated with ZO-1 (1:100 dilu-
tion, Invitrogen, Carlsbad, CA, USA) and CD31 (1:200 di-
lution, R&D Systems, Minneapolis, MN, USA); occludin
(1:100 dilution, Invitrogen, Carlsbad, CA, USA) and
CD31; claudin-5 (1:100 dilution, Invitrogen, Carlsbad, CA,
USA) and CD31 at 4°C overnight. After washing, brain
sections were incubated with the appropriate second anti-
bodies for 1 hour. Brain sections were examined using a
confocal microscope (Leica, Solms, Germany) and photo-
graphs were taken for further analysis.
DAB staining: for myeloperoxidase (MPO), ICAM-1 and
Gr1 (Ly 6G) immunostaining, brain sections were incu-
bated in 0.3% H2O2 in methanol for 30 minutes. After
blocking with FBS, the primary anti-body MPO (1:300 dilu-
tion, R&D Systems, Minneapolis, MN, USA) and ICAM-1
(1:200 dilution, R&D Systems, Minneapolis, MN, USA),
Gr1 (1:100 dilution, Millipore, Darmstadt, Germany) were
incubated overnight at 4°C. Sections were incubated with
biotinylated-conjugated secondary antibody (Vector La-
boratories, Burlingame, CA, USA) and then incubated with
Vectastain ABC Reagent. The reaction product was vi-
sualized using a DAB substrate (Vector Laboratories,
Burlingame, CA, USA). Eight interested fields in each
ipsilateral hemisphere, including the perifocal region in
both cortex and striatum, were photographed in each
section and five consecutive sections spaced at 200 μm
were counted in each mouse. MPO+ and Gr1+ (Ly 6G)
cells were counted in each field by a person blinded tothe treatment group. IgG leakage was examined as pre-
viously reported and the procedure was similar to MPO
staining except for the primary antibody incubating
process [23]. Four areas of ischemic penumbra from
each slide were photographed. And mean optical dens-
ity was measured using Image-Pro Plus software (Media
Cybernetics, Bethesda, MD, USA).
Western blot analysis
Samples were lysed in radioimmunoprecipitation assay
(RIPA) (Millipore, Bedford, MA, USA) supplemented with
1 mmol/L PMSF (Thermo, Waltham, MA, USA), cocktail
(Thermo, Waltham, MA, USA) and phosphatase inhibitor
(Thermo, Waltham, MA, USA). For Western blot ana-
lyses, samples containing the same amount of proteins
were loaded onto the resolving gel (Promoton, Shanghai,
China) for electrophoresis after denaturing. Proteins were
transferred onto a nitrocellulose membrane (Whatman,
Piscataway, NJ, USA). After being blocked with 5% non-fat
milk, the membrane was incubated with primary antibodies
at the following dilution MPO (1:500), ICAM-1 (1:2,000),
ZO-1 (1:500), occludin (1:500), claudin-5 (1:500), p-AMPK
(1:1,000, Cell Signaling Technology, Beverly, MA, USA),
AMPK (1:1,000, Cell Signaling Technology, Beverly,
MA, USA), p-NF-κB (1:1,000, Cell Signaling Technol-
ogy, Beverly, MA, USA), NF-κB (1:1,000, Cell Signaling
Technology, Beverly, MA, USA), β-actin (1:1,000, Santa
Cruz Technology, Santa Cruz, CA, USA) at 4°C overnight,
respectively. After washing, the membrane was incubated
with the appropriate horseradish peroxidase (HRP)-conju-
gated secondary antibody for 1 hour and then reacted with
enhanced chemiluminescence substrate (Pierce, Rockford,
IL, USA). The results were recorded by Quantity One
image software (Bio-Rad, Hercules, CA, USA) and relative
intensity was calculated using Gel-Pro Analyzer software
(Media Cybernetics, Bethesda, MD, USA).
MPO activity assay
MPO activity assay was performed as described previously
[23]. In brief, brain protein (10 μL) from ipsilateral hemi-
sphere was added to 180 μL of work solution, which con-
tained 2 mmol/L O-dianisidin-dihydrochloride (Sigma)
dissolved in 180 μl of 50 mmol/L potassium phosphate buf-
fer (pH =6). Before measurement, 10 μL of 100 mmol/L
H2O2 was added. Changes in absorbance at 460 nm over
10 minutes were measured. MPO activity was expressed
as U/mg tissue, and 1U of MPO activity represents the
amount of enzyme degrading 1 μmol H2O2 per minute
at 25°C.
Real-Time PCR
Total RNA from the ischemic hemisphere was extracted
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
and dissolved in 60 μL RNA free water according to the
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cycling condition was used: 95°C for 30 seconds followed
by 40 cycles of 95°C for 5 seconds and 60°C for 30 sec-
onds. mRNA levels were normalized to the endogenous
control, GAPDH expression, and were calculated using
fold change relative to the saline control group [23].
Enzyme Linked Immunosorbent Assay (ELISA) analysis
Protein levels of IL-1β, IL-6, and TNF-α were quantified
using an ELISA kit (R&D systems, Minneapolis, MN,
USA) according to the manufacturer’s instruction. Ab-
sorbance at 450 nm was recorded and the concentration
of the target protein was read according to the standard
curve. Result was expressed as pg/mg protein.
Evans blue extravasation
Evans blue extravasation was measured as previously de-
scribed. In brief, 3 days after tMCAO, 4 ml/kg of 2% Evans
blue (Sigma, St. Louis, MO, USA) in saline was adminis-
tered intraperitoneally. After 2 hours circulation, mice were
anesthetized and perfused with saline through the left ven-
tricle until colorless fluid outflowed from the right atrium.
Then, ipsilateral and contralateral hemispheres were col-
lected after decapitated. Each hemisphere was weighed
rapidly, homogenized in 1 ml of 50% trichloroacetic acid
(wt/vol). After centrifugation (12,000 × g, 20 minutes),
supernatant was collected and mixed with ethanol (1:3).
The concentration of Evans blue was determined by meas-
uring the 610 nm absorbance and tissue content of Evans
blue was quantified from a linear standard curve and
expressed in terms of Evans blue (μg)/tissue (g).
Oxygen glucose deprivation
bEND.3 was purchased from American Type Culture
Collection (ATCC) and cultured in DMEM (Gibco La-
boratories, Grand Island, NY, USA) supplemented with
10% FBS. Ischemia-like conditions in vitro were induced
by oxygen glucose deprivation and reperfusion-like con-
ditions in vitro were induced by reoxygenation. After
cells reached a 90% confluence, the medium was replaced
with DMEM without glucose. Then, cultures were trans-
ferred to an anaerobic chamber infused with a gas mixture
containing 5% CO2, 95% N2. After incubating for 6 hours,
cells were further cultured in DMEM supplemented with
10% FBS under normal conditions for another 24 hours
with or without metformin. p-AMPK analysis in bEND.3
cells was determined 1 hour, 4 hours, and 24 hours after
6 hours oxygen glucose deprivation (OGD). The dose used
was 10 mM, which was chosen according to previous re-
ports [20]. Compound C (Sigma, St. Louis, MO, USA), a
selective AMPK inhibitor was added to the medium at a
final concentration of 10 μmol/L before OGD treatment
and maintained throughout the whole experiment [24].
An equal volume of PBS was used in the control group.Statistical analysis
Results were presented as mean ± SD. Statistical analysis
was evaluated by Prism 4 software (GraphPad Software,
San Diego, CA, USA). For comparison between the two
groups, statistical significance was determined through a
Student's t test. For comparison among multiple groups,
statistical significance was evaluated using one-way ANOVA
followed by a Student-Newman-Keuls test. A probability
value of P < 0.05 was considered statistically significant.
Results
Metformin reduced infarct volume and improved
neurobehavioral outcomes
We found that after metformin treatment, infarct volume
was reduced at 1 and 3 days after tMCAO (Figure 2A-B).
To further explore the function of metformin, we used
mNSS to examine the motor, balance and reflex functions
of mice after tMCAO. We showed that mice had
significantly lower scores after 3 days in the metformin-
treated group after tMCAO for at least 14 days
(Figure 2C). A similar result was obtained from the
rotarod test (Figure 2D). To investigate whether met-
formin influenced glucose levels after tMCAO, fasting
blood-glucose (FBG) was tested before, 3 days and
14 days after tMCAO, indicating metformin did not
influence FBG level, blood gas or body weight after
both 3 (Table 1) days and 14 days treatment (Data
were shown in Additional file 1: Table S1)
Metformin alleviated neutrophil infiltration and IL-1β,
IL-6, TNF-α expression
To investigate the effect of metformin on neutrophil in-
filtration in the acute phase of cerebral ischemia, we
performed 3,3’-diaminobenzidine (DAB) staining to de-
tect MPO+ cells. Results showed MPO+ cells were al-
most undetectable in the sham group, and there was a
decrease in MPO+ cells at 1 and 3 days after tMCAO in
the metformin-treated group compared to the control
group (Figure 3D). Western blot analysis indicated that
MPO were reduced in metformin-treated mice (P < 0.01,
Figure 3E). MPO activity is an indicator of inflammation
and could be used to evaluate neutrophil accumulation
[23]. MPO activity was attenuated in the metformin-
treated group compared to the control group (P < 0.05,
Figure 3C). In addition, we used another neutrophil
marker Gr1 (Ly 6G) to evaluate neutrophil infiltration
after cerebral ischemia. Results showed that metformin re-
duced Gr1 positive cells effectively at 1 day and 3 days
after tMCAO (Additional file 2: Figure S1, P < 0.01). We
further used RT-PCR and ELISA to evaluate changes in
inflammation-related cytokine expression in mRNA and
protein levels. Metformin reduced IL-β, IL-6, TNF-α
mRNA at 1 day after tMCAO. Although there was a
downward tendency in IL-6 mRNA, only changes in IL-β,
Figure 2 Metformin reduced infarct volume and improved neurobehavioral outcomes following transient middle cerebral artery (tMCAO)
in mice. (A) Photographs show a series of coronal sections with cresyl violet staining following tMCAO in metformin- and saline-treated mice. (B) Bar
graph shows a quantification of the infarct volume from (A). n =6 per group. The changes in neurological scores (C) and the rotarod test (D) at 1, 3, 7
and 14 days following tMCAO in metformin- and saline-treated mice. n =9 per group, data are mean ± SD, *P < 0.05, metformin versus control group,
**P < 0.01, metformin versus control group.
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group compared to the control group at 3 days after
tMCAO (Figure 3A). There was a decrease of IL-β, IL-6,
TNF-α expression at 3 days after tMCAO in protein level
(Figure 3B, P < 0.01).Table 1 Metformin did not influence blood gas, glucose
level and body weight in transient middle cerebral artery
occlusion (tMCAO) mice
Before tMCAO After tMCAO
NS Met NS Met
pH 7.35 ± 0.05 7.34 ± 0.03 7.34 ± 0.07 7.35 ± 0.03
PCO2 (mmHg) 38 ± 5 33 ± 3 30 ± 7 30 ± 5
PO2 (mmHg) 62 ± 4 60 ± 7 64 ± 2 66 ± 12
SO2 (%) 91 ± 8% 87 ± 10% 91 ± 2% 91 ± 5%
Na(mmol/L) 155 ± 2 153 ± 2 154 ± 3 152 ± 2
K (mmol/L) 3.2 ± 0.1 3.1 ± 0.4 3.5 ± 0.3 3.9 ± 0.2
iCa (mmol/L) 1.37 ± 0.02 1.34 ± 0.06 1.22 ± 0.04 1.26 ± 0.04
Glu (mg/dL) 132 ± 20 127 ± 33 123 ± 16 129 ± 24
Hct (%PCV) 37 ± 1% 35 ± 1% 34 ± 6% 35 ± 2%
Hb (g/dL) 12.4 ± 0.4 11.9 ± 0.3 11.4 ± 2.2 11.8 ± 0.7
Body weight (g) 33 ± 2 32 ± 1 25 ± 6 28 ± 4
Table showed vein blood gas analysis results, glucose levels and body weight
at 1 day before tMCAO and at 3 days after tMCAO in metformin-(Met) and
saline(NS)-treated mice (n =4 per group). Data were mean ± SD.
Legend: Glu, glucose; Hb, hemoglobin; Hct, hematocrit; PCO2, partial pressure of
CO2; PO2, partial pressure of O2; PCV, packed cell volume; SO2, oxygen saturation.Metformin reduced BBB disruption
To evaluate endothelial cell permeability after metformin
treatment, we conducted occludin/CD31, ZO-1/CD31 and
claudin-5/CD31 double staining to observe tight junction
distribution in situ at 3 days after tMCAO. Result indi-
cated that occludin and ZO-1 were continuously located
on the margin of ECs in sham group, claudin-5 was con-
tinuously located along ECs, and fewer gaps were formed
in the metformin-treated group (Figure 4A). Gap forma-
tion and rearrangement were used to evaluate tight junc-
tion disruption after injury. To evaluate tight junction
rearrangement, Western blot was adopted and we found
that metformin-treated mice demonstrated occludin, ZO-
1 and claudin-5 hyper-expression (Figure 4B). In addition,
we performed IgG immunostaining and Evans blue ex-
travasation to evaluate endothelial permeability and found
that there was significantly reduced IgG and Evans blue
leakage at 3 days after tMCAO in metformin-treated mice
(Figure 4C-D).
Metformin down-regulated ICAM-1 expression via AMPK
signaling pathway
To assess the phosphorylation status of AMPK at threonine
residue, Western blot was used. We demonstrated that
ischemia-reperfusion increased AMPK phosphorylation
and this induction was increased after metformin treatment
(Figure 5A). To further explore mechanisms of metformin
in neuroprotection, we analyzed ICAM-1 expression after
Figure 3 Metformin alleviated neutrophil infiltration and inflammatory cytokine expression in mice. (A) Relative fold changes of inflammatory
cytokines (IL-1β, IL-6, TNF-α in metformin and control mice at 1 (left) and 3 days (right) following tMCAO (n =3 per group). (B) Protein level of inflammatory
cytokines IL-1β, IL-6, TNF-α expression in metformin and control mice at 3 days following tMCAO (n =3 per group). (C) Bar graph shows MPO activity in
metformin and control mice (n =3 per group). (D) MPO+ cells (arrows) and their quantification in sham group, control and metformin-treated mice at 1
and 3 days following tMCAO. Scale bar =100 μm. (E) Western blot of MPO expression in metformin and control mice. Bar graph shows a quantification of
MPO. Data are mean ± SD, *P< 0.05, **P< 0.01, metformin versus control group.
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in ECs, and after cerebral ischemia its expression was
elevated hugely (Figure 5D). Furthermore, Western blot
and RT-PCR results indicated that ICAM-1 was reduced
after metformin-treatment compared to the control group
(Figure 5B-C). We also found that metformin inhibited
NF-κB phosphorylation at 1 day and 3 days after tMCAO
(Figure 5E). To determine whether metformin-induced
down-regulation of ICAM-1 was AMPK-dependent or
not, we analyzed the effect of metformin at a cellular level,
using OGD models to mimic in vivo ischemia/reperfusion
injury. First, we treated bEND.3 cells with metformin to
determine whether metformin could also increase p-
AMPK in vitro. We found that there was an increase in p-
AMPK expression at 60 and 120 minutes after metformin
treatment: the maximum effect was at 60 minutes in nor-
mal conditions (Figure 6A) and while treatment withmetformin after 6 hours of OGD, there was also an in-
crease in p-AMPK expression 1 hour after reoxygenation
and p-AMPK levels were unregulated for at least 24 hours
after reoxygenation (Figure 6B). Second, we examined
ICAM-1 expression after 6 hours of OGD and reoxygena-
tion with or without metformin. After OGD/reoxygena-
tion treatment, ICAM-1 expression was up-regulated in
mRNA level and metformin inhibited this up-regulation:
the inhibitive effects began at 4 hours after reoxygenation
and were sustained for at least 24 hours after reoxygena-
tion (Figure 6C). To test whether AMPK signaling was in-
volved, a selective AMPK inhibitor, compound C, was used
to block the AMPK phosphorylation. First, we found that
compound C reduced metformin-induced AMPK phos-
phorylation, then, we used RT-PCR and Western blot to as-
sess ICAM-1 expression after treatment. Results indicated
that metformin reduced ICAM-1 expression in both
Figure 4 Metformin promoted ZO-1, occludin and claudin-5 rearrangement and lessened IgG and Evans blue extravasation. (A) Occludin,
ZO-1 and claudin-5 expression in sham group, NS and metformin-treated mice at 3 days following tMCAO. Scale bar =10 μm. (B) Representative result of
occludin, ZO-1 and claudin-5 expression at 1 and 3 days after tMCAO. Bar graphs show a quantification of occludin, ZO-1 and claudin-5 expression.
(C) IgG leakage at 3 days following tMCAO in saline and metformin-treated group. Higher magnifications are shown below. Boxes displayed
representative IgG staining. Scale bar =1 mm (upper) and 100 μm (lower). Bar graph shows a semi-quantification of integrated optical density
(IOD) of IgG at 1 and 3 days after tMCAO (n =3 per group). (D) Images show Evans blue extravasation in sham (a), saline (b) and metformin (c)
group at 3 days after tMCAO. Blue area indicates extravasation of Evans blue. Bar graph shows a quantification analysis of Evans blue contents
in brain tissue (n =3 per group). Data were mean ± SD, *P < 0.05, metformin versus saline group, **P < 0.01, metformin versus saline group.
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ditions (Figure 6D-E). Furthermore, we used Western blot
to evaluate the effects of metformin on NF-κB activation;
the result indicated that metformin inhibited NF-κBphosphorylation and this function was abolished by com-
pound C (Figure 6G). Thus, we concluded that metformin
diminished ICAM-1 via an AMPK mediated signaling
pathway and AMPK-NF-κB might be involved.
Figure 5 Metformin promoted phosphorylation of AMPK and reduced ICAM-1 expression in transient middle cerebralartery occlusion
(tMCAO) mice. (A) p-AMPK and AMPK expression in sham, saline- and metformin-treated groups at 1 day after tMCAO. Bar graph showed a
quantification of p-AMPK/AMPK ratio (n =3/group). (B) ICAM-1 expression and quantification at 1 and 3 days after tMCAO in metformin and
control mice (n =3 per group). (C) Fold change of ICAM-1 expression in mRNA level in metformin and control mice at 1 day and 3 days after tMCAO
(n =3 per group). (D) ICAM-1 expression in control and metformin-treated mice at 1 and 3 days after tMCAO. Arrows indicated representative ICAM-1
expression. Scale bar =100 μm. (E) p-NF-κB and NF-κB expression in saline- and metformin-treated groups at 1 day and 3 days after tMCAO. Bar graph
show a quantification of p-NF-κB/NF-κB ratio (n =3 per group). Data are mean ± SD, *P < 0.05, metformin versus control, sham versus control group,
**P < 0.01, metformin versus control group.
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In the present study, we demonstrated that metformin pro-
tected the brain from ischemic injury through alleviating
inflammatory responses in tMCAO mice, thus improving
long-term recovery. Metformin diminished neutrophil infil-
tration, thereby alleviating endothelial injury and lowering
BBB permeability. These effects were potentially mediated
via an AMPK-dependent ICAM-1 down-regulation. We
also found that inhibiting AMPK activation by compound
C could reverse metformin-induced down-regulation of
ICAM-1 in vitro. Thus, we concluded that metforminexerts its protective effect after cerebral ischemia partly
through diminished ICAM-1 expression.
Metformin is a glucose-lowering agent, and is one of the
first-line drugs recommended to treat type II diabetes mel-
litus [25]. The UK Prospective Diabetes Study (UKPDS)
has revealed that metformin reduced the risk of all-cause
mortality and stroke clinically; however, these benefits
were independent of its anti-hyperglycemic effects, since
metformin reduced glycated hemoglobin (HbA1c) to the
same extent as sulphonylurea and insulin [5]. Metformin
decreased myocardial injury in non-diabetic and diabetic
Figure 6 (See legend on next page.)
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Figure 6 Metformin promoted phosphorylation of AMPK and reduced ICAM-1 expression in vitro in an AMPK-dependent manner. (A) p-AMPK
and AMPK expression and quantification at 30, 60 and 120 minutes after metformin treatment in vitro in normal conditions. (B) p-AMPK and
AMPK expression and quantification in control, 1, 4 and 24 hours in reoxygenation group in the presence of metformin in vitro. (C) Fold change
of ICAM-1 expression in mRNA level 1, 4 and 24 hours after reoxygenation in saline- and metformin-treated group. (D) ICAM-1 expression in
mRNA after metformin and AMPK inhibitor and compound C treatment in the oxygen glucose deprivation (OGD) model. (E) ICAM-1 expression and
quantification after metformin, AMPK inhibitor and compound C treatment in OGD model. (F) p-AMPK and AMPK expression and quantification after
metformin and compound C treatment in OGD model. (G) p-NF-κB and NF-κB expression and quantification after metformin and compound C
treatment in OGD model. Data were mean ± SD, *P < 0.05, **P < 0.01. Representative results from three independent experiments are shown. Com.
C = compound C.
Liu et al. Journal of Neuroinflammation 2014, 11:177 Page 10 of 12
http://www.jneuroinflammation.com/content/11/1/177mice [4] and prevented the progression of heart failure in
dogs [10]. However, reports regarding neuroprotection of
metformin in cerebral ischemia were controversial. Using
a 90-minute tMCAO model, McCullough demonstrated
that chronic treatment, both pre- and post- (3 weeks),
with metformin reduced infarct volume effectively; how-
ever, pre-treatment (3 days) enhanced injury in ischemic
stroke [26]. Harada et al. showed that using 3-day metfor-
min treatment after 2 hours of tMCAO, metformin effect-
ively reduced infarct volume [27], which was consistent
with our result. In addition, Li has suggested that chronic
treatment (14 days in drinking water, 300 mg/kg) with
metformin in diabetic rats was protective, but acute treat-
ment (1 day in drinking water, 300 mg/kg) exerted differ-
ent effects [28]. However, we must note that different
models were used. For acute treatment, 3-hour occlusion
and 21 hours reperfusion model were used; however, for the
chronic treatment, a 90-minute occlusion and 14 days re-
perfusion model was adopted, and glucose level was normal
in chronic treatment rats. Thus, different animal strains and
different models may explain the different effects observed
from different studies [26]. In our study, using a 90-minute
tMCAO model in mice and treatment at the time of reper-
fusion, we demonstrated that metformin could alleviate
ischemic injury and improve neurobehavioral outcomes.
We demonstrated the protection by metformin on is-
chemic stroke involved, at least in part, AMPK activity
[3]. However, McCullough’s group found that metformin
enhanced ischemic injury in tMCAO animals in a 3-day
precondition study through activating AMPK [26]. We
believe this result can be due to the period of treatment.
Metformin could increase AMPK phosphorylation both
in vitro and in vivo [4,9]. We detected an induction of
AMPK phosphorylation in both bEND.3 cells and the
mouse brain after tMCAO. Notably, conditions that
could activate AMPK have been proven to be beneficial
in stress, particularly in ischemia. Ischemic precondition,
which can activate AMPK due to an increase of the
AMP/ATP ratio, is supposed to be protective in ischemic
stroke [29]. Adiponectin reduces infarct size in cerebral is-
chemia and myocardial injury has been shown to be partly
through promoting AMPK phosphorylation [30,31]. In
addition, AMPK involves pleiotropic pathways that play
critical roles in cerebral ischemia. Through suppression ofthe mTOR signaling pathway, AMPK regulates cell
growth and autophagy [7]. Via activation of the Nrf2/
SKN-1 signaling pathway, AMPK increases antioxidant
gene expression [32]. By promotion of the eNOS pathway,
AMPK reduces endothelial cell apoptosis and improves
endothelial functions [9]. Furthermore, emerging evidence
shows that AMPK is beneficial to neurons suffering from
injuries such as ischemia, starvation, and oxidative damage
[11]. Collectively, these results suggest that metformin-
AMPK signaling pathways exert protective effects in stress
conditions and protect the brain from ischemic stroke.
The mechanism by which metformin reduces inflamma-
tion after cerebral ischemia is poorly understood. ICAM-1
expression can be regulated by the nuclear transcriptional
factor NF-κB [33]. Recently, the potency of metformin
blocking NF-κB signaling has been illustrated [34]. In
addition, metformin decreased TNF-α-induced ICAM-1
by inhibiting NF-κB activation in ECs [12]. Therefore, we
suppose that metformin reduced ICAM-1 expression via
the AMPK-NF-κB pathway. We also detected an inhib-
ition of NF-κB activation after metformin treatment both
in vivo and in vitro. Previous study showed that there was
a huge increase of ICAM-1 expression at the time of re-
perfusion; in our study, metformin was administrated at
the time of reperfusion. Increased expression of adhesion
cytokine is detrimental during ischemic injury since it in-
creases neutrophil adhesion to ECs and thus promotes
their infiltration [16]. Anti-ICAM-1 treatment significantly
reduced infarct volume [15]. Coincidently, we demon-
strated that metformin decreased ICAM-1 both in vivo
and in vitro, and this reduction in ICAM-1 in vivo was ac-
companied by alleviated neutrophil infiltration and re-
duced infarct size in tMCAO mice. Furthermore, our
study indicated that this effect was possibly mediated by
AMPK in a dependent manner. We concluded that met-
formin conferred resistance to ischemic stroke through
decreasing ICAM-1 via the AMPK signaling pathway.
Besides increasing inflammation, neutrophil infiltration
also induces EC injury and increases BBB permeability
[35]. BBB disruption exacerbates brain injury after ische-
mia. Injuries such as ischemia and trauma lead to a dis-
ruption and reconstruction of ZO-1 and occludin, and an
increase in BBB permeability [23]. Reduction of BBB per-
meability alleviates cerebral ischemia injury in both
Liu et al. Journal of Neuroinflammation 2014, 11:177 Page 11 of 12
http://www.jneuroinflammation.com/content/11/1/177transient and permanent cerebral ischemia [19,22,23]. Re-
cently, it has been reported that metformin-induced im-
provement of BBB functions in ECs in vitro is due to
activating AMPK activity [24]. In the present study, we
demonstrated that after metformin treatment, IgG and Ev-
ans blue leakage was significantly reduced and tight junc-
tion protein profoundly increased, leading to better
outcomes in tMCAO mice.
Conclusions
We demonstrated that metformin is beneficial to the
treatment of ischemic stroke, which is possible through
inhibiting inflammation via AMPK signaling pathways.
Since metformin is a widely used drug with few adverse
effects, using this long-established drug for a new use
may be a promising way to develop an effective therapy
for ischemic stroke [36]. Metformin has the potential to
be useful in the clinical treatment of ischemic stroke.Additional files
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